2-fluorofucose

Drug Profile

2-fluorofucose

Alternative Names: 2-fluorofucose peracetate; 2FF; SGD-2083; SGN-2FF

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Carbohydrate metabolism inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO)
  • 31 Oct 2016 Seattle Genetics plans a phase I trial for Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT02952989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top